Introduction
Over the last decades advanced progress in biotechnology and pharmaceutical industry has been translated into the development of so-called biologic drugs, in particular monoclonal antibodies and fusion proteins. Based on their unique properties such as the exquisite selectivity with high affinity to the target, biologic molecules constitute a novel class of therapeutic agents which have transformed the management of a variety of refractory chronic rheumatic, gastrointestinal and cutaneous inflammatory disorders. As the routine administration of these regimens is expanding, the potential of fulfilling the growing and unmet needs in the treatment of chronic pain have prompted physicians to implement similar approaches in patients suffering from conditions not characterised by systemic inflammation such as osteoarthritis (OA) [1] .
OA is probably the most common rheumatic condition affecting humans, characterized by chronic joint pain and considerable functional impairment as available pharmacological and non-pharmacological treatments have so far been of very limited value [2] . Although OA has historically been considered as a non-systemic inflammatory condition, a growing body of evidence supports the involvement of pro-inflammatory cytokines cascades in the development of cartilage degradation and loss, bone resorption and various levels of local, mainly synovial inflammation. Particularly, interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) which are abundantly produced in osteoarthritic joints affect synoviocytes and chondrocytes to synthesize and excrete mediators and effectors of bone and synovial tissue turnover [3, 4] . This inflammatory environment limits the capacity of chondrocytes to self-repair, and the ensuing imbalance between loss of cartilage and remodeling results in irreversible cartilage damage and matrix degradation (Figure 1 ). Besides pro-inflammatory properties, TNF-alpha also activates central augmentation of pain and interacts with other neuro-inflammatory signaling systems and growth factors which are considered as key mediators in neuropathic component of osteoarthritic pain [5] .
[Insert Figure 1 here] Nerve growth factor (NGF) was the first discovered neurotrophic factor and it was primarily identified for its role in differentiation and survival of neurones in perinatal and early postnatal periods [6] . Recently, much focus has been given to its role in the perpetuation of chronic pain [7] [8] [9] . NGF is a secreted 13-kDa soluble neurotrophin polypeptide [10] . It binds to a non-selective 75 kDa neurotrophin receptor and a highaffinity NGF-selective tyrosine kinase receptor that are expressed on pain-transducing cells called nociceptors. Nociceptors send impulses to the central nervous system, where the conscious perception of pain is coordinated and appropriate physiological response is initiated. In the context of OA the upregulation of TNF and IL-1 in degenerated joints directly induce the expression of NGF in the inflamed tissue leading to increased overall activity of peripheral nociceptors and pain perception [11] . NGF also mediates pain indirectly by recruiting pro-inflammatory immune cells such as mast cells [12] that produce bradykinin, prostaglandin and NGF itself [13] . Intra-articularly, NGF upregulates local production of substance P and calcitonin gene-related peptide (CGRP), both of which are known to induce joint inflammation and degeneration. Although effective blockade of NGF does not directly promote joint tissue regeneration in osteoarthritic joints, a reduction in inflammatory processes could allow for self-repair.
Additionally, anti-NGF reduces both sensitivity to pain and frequency of spontaneous pain and this analgesic effect may also improve functionality and overall quality of life in patients.
Experimental and clinical studies confirming the role of anti-NGF in the pain pathway [8] [9] [10] as well as the appreciation that the inflammatory cytokine network contributes to the pathogenesis of OA [14] have underpinned the rationale for studies investigating whether such novel treatment approaches represent a potential treatment option for OA pain. Most of the trials have focused on TNF-alpha inhibitors but there are also reports with other anti-cytokine agents investigating the ability of biologic-based therapies to ameliorate pain in these highly prevalent and debilitating diseases. This review discusses the current knowledge on the use of biologic agents, specifically anti-TNF and anti-NGF for the management of osteoarthritis.
Methods
A MEDLINE and EMBASE search up to October 2016 was conducted according to published guidance on narrative reviews [15] . A combination of both indexing and free text terms was used including osteoarthritis, anti-TNF, anti-NGF, and growth factors.
Studies were selected for inclusion if evaluating the use of biologic agents for the management of osteoarthritis. The search was restricted to articles published in English language but also included abstracts submitted in international congresses. A hand search of the reference lists of studies meeting the inclusion criteria was also performed to identify additional relevant reports.
Results

Tumour necrosis factor alpha inhibition
Given the dramatic effect of TNF-alpha inhibition on pain and structural damage in patients with inflammatory arthropathies, rheumatologists have tried to adopt similar therapeutic approaches for patients with osteoarthritis, predominantly individuals with erosive hand disease. However two double-blind, placebo-controlled trials did not demonstrate any superiority of adalimumab compared to placebo in patients with hand
OA not responding to analgesic or anti-inflammatories in a follow-up period of 6-12 months [16, 17] . In these studies TNF-alpha inhibition did not have any effect on structure modification, pain experience, number of painful or swollen joints nor reduced the consumption of analgesics in patients with OA; notably adalimumab halted the progression of bone erosions in the subgroup of patients with clinically swollen distal interphalangeal joints at baseline [16] . More recently a double-blind, placebo-controlled trial evaluating the efficacy of subcutaneous etanercept in patients with erosive OA of the hands provided promising results regarding the ability of the drug to improve pain and modify structural damage, again in patients with more symptomatic, inflammatory disease [18] . In the same study, etanercept was effective in improving bone marrow lesions predominantly in interphalangeal joints with inflammation at baseline, in a small number (n=20) of patients who underwent magnetic resonance imaging [19] . However in the whole study population, no difference between etanercept and placebo was observed in visual analogue score pain at 24 weeks. Open-label studies have reported similar results [20] with the exception of a single-blind study on 10 patients in which intraarticular injection of infliximab reduced joint pain and tenderness on palpation when individual joints were assessed [21] . Intraarticular administration of the IL-1 receptor antagonist, anakinra, failed to provide clinical benefit in patients with knee OA in a double-blind placebo RCT [22] . Table 1 summarizes the studies employed anti-cytokine biologic drugs in OA individuals. 
Nerve growth factor inhibition
The potential use of anti-NGF has been explored in several chronic pain conditions but osteoarthritis of the hip and knee being the primary indication for the majority of clinical trials ( 
Discussion
Over the last decades advances in the understanding of OA pathophysiology have illustrated that inflammatory cytokine network is substantially involved in initiation and propagation of structural bone and cartilage tissues changes. Therefore the use of biologic molecules targeting specific inflammatory and pain signaling pathways to ameliorate chronic osteoarthritic pain is based on a sound rationale.
Clinical research results however did not meet the expectations as three double blind placebo controlled studies conducted in patients with erosive inflammatory arthritis of the hands failed to demonstrate superiority of TNF-alpha inhibitors in terms of pain scores and functional improvement [16, 18, 20] . On the other hand the findings of these trials indicate that specific subsets of OA individuals with erosive hand disease may benefit from biologic drugs. Particularly the subset of patients with a pronounced inflammatory element contributing to the symptoms appear to respond better and more importantly may represent the best target population for future trials. In that respect recent reports from ultrasound based studies suggesting that ultrasound determined synovitis in the small joints of the hands is an independent predictor of the development of joint erosions at 2
[39] and 4 years [40] lend more support to the concept that enhanced residual inflammatory activity may represent a potential target for research in this particular subgroup of patients.
Of course the launch of future studies investigating the effect of TNF-alpha inhibition on OA should be considered against the background of limitations particularly in view of high costs. The limited effect of biologic drugs demonstrated to-date raises doubts for the cost-effectiveness of trials in this field, however the high economic burden and the social consequences associated with OA [41] as well as the failure of other treatment approaches -for example a recently presented negative double blind placebo-controlled hydroxychloroquine trial [42] -emphasize the need for better therapeutic strategies in OA, still a neglected disease [43] . Current financial constraints mandate the implementation of value-based medicine and in this regard the identification of patients more likely to benefit from biologic drugs using ultrasound as a screening tool for future trials and the potential introduction of biosimilars [44] may reduce the costs of biotherapy given that RCTs with hard end-points may confirm the effectiveness of these regimens in OA of the hands.
Whereas NGF blockade has been quite effective in patients with OA of the knee and the hip, safety considerations forced US Food and Drug Administration (FDA) to suspend trials on anti-NGF mAb in 2010 due to reported cases of osteonecrosis that led to total joint replacement, and severe peripheral neuropathy in trials. The adverse event profile in other anti-NGF trials for osteoarthritis, which suggested class effect, was particularly crucial in tipping the FDA's decision to suspend the trials except for patients with terminal cancer [45] . Although the FDA decision has been reversed in 2012, the concern over adverse events remains. No clear association between anti-NGF and osteonecrosis has been demonstrated as rapidly progressive joint degeneration can be considered as a natural course of OA in some patients and osteonecrosis can also co-exist with OA at some stage [46] . Osteonecrosis has not been observed in trials assessing the effect in other chronic conditions, demonstrating the importance of patient characteristics [47] .
Another proposed indirect reason for the relatively higher incidence of joint destruction in patients receiving anti-NGF is based on the assumption that pain reduction encourages increased joint activity and overloading [45, 48] . A recent animal model seems to support this idea [49] . While these are plausible reasons, OA treatments should aim to reduce pain and, to a reasonable extent, improve function. Successful treatments may result in patients resuming normal activity which may inadvertently lead to additional pressure on the joint. As with any other drug, the benefit-risk ratio of treatment with anti-NGF for OA should therefore be carefully considered by clinicians and patients.
Although data is inconsistent, it appears that biologic molecules are not effective in 
Conclusion
Optimal Activated macrophage synoviocytes and chondrocytes produce pro-inflammatory mediators which in turn activate peripheral nociceptors that innervate the synovial capsule, periosteum and subchondral bone contributing to peripheral sensitization and hyperexcitability of nociceptive neurons in the central nervous system. Neurotrophic factors, predominantly NGF further exacerbate joint destruction process and inflammation by upregulating neuropeptides such as calcitonin gene-related peptide and substance P which promote mechanical sensitization of the joint. Blockade of these pathways may diminish the degree of immune responses with direct and indirect beneficial effects on joint degeneration and pain perception. Cytokine-targeted pathways reduce the synthesis and release of intra-articular mediators while inhibition of NGF-mediated pathways may result in the reduction of synovial inflammation and alleviation of pain symptoms.
IL-1: interleukin-1, NGF: nerve growth factor, TNF-alpha: tumor necrosis factor-alpha.
